CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Zhijun Yuan, Shanshan Weng, Chenyang Ye, Hanguang Hu, Suzhan Zhang, Ying Yuan

2022, 34(2): 67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01

Prognostic and incremental value of computed tomography-based radiomics from tumor and nodal regions in esophageal squamous cell carcinoma

Bangrong Cao, Kun Mi, Wei Dai, Tong Liu, Tianpeng Xie, Qiang Li, Jinyi Lang, Yongtao Han, Lin Peng, Qifeng Wang

2022, 34(2): 71-82. doi: 10.21147/j.issn.1000-9604.2022.02.02

Genomic landscape of T-cell lymphoblastic lymphoma

Zhaoming Li, Yue Song, Mingzhi Zhang, Yiming Wei, Hang Ruan

2022, 34(2): 83-94. doi: 10.21147/j.issn.1000-9604.2022.02.03

Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics

Tongxia Wang, Yan Gao, Xi Wang, Junrui Tian, Yuan Li, Bo Yu, Cuiyu Huang, Hui Li, Huamao Liang, David M. Irwin, Huanran Tan, Hongyan Guo

2022, 34(2): 95-108. doi: 10.21147/j.issn.1000-9604.2022.02.04

Current status and perspectives of conversion therapy for advanced gastric cancer

Heli Yang, Ke Ji, Jiafu Ji

2022, 34(2): 109-114. doi: 10.21147/j.issn.1000-9604.2022.02.05

Pan-cancer tumor-infiltrating T cells: A great hallmark in cancer immunology research

Anqiang Wang, Zhaode Bu

2022, 34(2): 115-116. doi: 10.21147/j.issn.1000-9604.2022.02.06

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer

Yuehua Liang, Xiaoran Liu, Kun Li, Huiping Li

2022, 34(2): 117-130. doi: 10.21147/j.issn.1000-9604.2022.02.07